Seoul, Korea - Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities will present a technical session on Global Trial Solutions for Biotechs at BIOPLUS-INTERPHEX KOREA 2023 for biotechs planning regional or global trials. 

Novotech’s Vice President, Global Head of Clinical Services Yooni Kim will open the session which will be followed by presentations from senior Novotech experts.

• “Pre-Clinical requirements for successful clinical trial entry” – presented by Dr. Babaji Yadav, Associate Director and Principal Toxicologist, Novotech Drug Development Consulting
• “Successful global clinical trial solutions for biotechs” – presented by HyunKyoung Kim, Project Director, Novotech

Then a panel discussion will follow lead by Yooni Kim and featuring biotech leaders and Novotech sector specialists.

Technical Session by Novotech
Time
: 3:10pm (Korea)
Date: 12 July, 2023

Book a meeting with the Novotech team here or attend the Technical Session.

The conference which is co-hosted by Korea Biotechnology Industry Organization and Reed Exhibition Korea (RX Korea), and supported The Ministry of Trade, Industry and Energy is expected to attract more than 10,000 participants, 250 pharmaceutical and biotech companies, 400 exhibitors and features more than 20 conference sessions.

Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. 

Novotech has been awarded a range of significant industry awards including a CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2022 award, and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed more than 45 Leading Site Partnership agreements over the last 3 years.

Media contact

关于 Novotech Novotech-CRO.com

Novotech(诺为泰)成立于 1997 年,立足亚太,面向全球,是专业的生物技术合同研究组织(CRO)。

诺为泰因其在行业内的突出贡献而备受赞誉,曾荣获多项殊荣,其中包括 2023 年 CRO 领导力奖 (CRO Leadership Award 2023) 、2023 年亚太地区细胞与基因治疗临床试验卓越奖 (Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023)和自 2006 年以来蝉联亚太地区合同研究组织年度公司奖 (Asia-Pacific Contract Research Organization Company of the Year Award)。

诺为泰是一家包含实验室、Ⅰ期临床中心、药物开发咨询服务和专业FDA法规服务的临床CRO,拥有超5,000 项临床项目经验,包括Ⅰ期至Ⅳ期临床试验。Novotech专注于服务在亚太、美国与欧洲等地进行临床试验的生物技术客户。Novotech目前在全球34个办公地点共拥有3000多名员工。

要了解更多信息或与专家团队成员交谈,请访问 www.Novotech-CRO.com